Prosthetic heart valve sales will strengthen through 2036, anchored by transcatheter heart valves at 46.0% of the product segment in 2026, driven by expanding clinical indications for TAVR procedures across surgical risk patient populations. The market was valued at USD 15.29 billion in 2025 and is expected to be worth USD 33.88 billion by 2036.